Skip to main content

Maze Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

MAZE$34.91+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURE PAGE

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

MAZE THERAPEUTICS, INC.
By:/s/ Jason Coloma
Jason Coloma, Ph.D.
Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Jason Coloma, Ph.D. and Courtney Phillips, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Jason ColomaChief Executive Officer and DirectorMarch 31, 2025
Jason Coloma, Ph.D.(Principal Executive Officer and Principal Financial Officer)
/s/ Amy BachrodtSVP, FinanceMarch 31, 2025
Amy Bachrodt(Principal Accounting Officer)
/s/ Charles HomcyDirectorMarch 31, 2025
Charles Homcy, M.D.
/s/ Nancy C. AndrewsDirectorMarch 31, 2025
Nancy C. Andrews, M.D., Ph.D.
/s/ Neil ExterDirectorMarch 31, 2025
Neil Exter
/s/ Sekar KathiresanDirectorMarch 31, 2025
Sekar Kathiresan, M.D.
/s/ Jonathan LimDirectorMarch 31, 2025
Jonathan Lim, M.D.
/s/ Richard SchellerDirectorMarch 31, 2025
Richard Scheller, Ph.D.
/s/ Catherine Angell SohnDirectorMarch 31, 2025
Catherine Angell Sohn, Pharm. D.
/s/ Daniel SpiegelmanDirectorMarch 31, 2025
Daniel Spiegelman
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.